Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research paper

Renin-angiotensin system at the heart of COVID-19 pandemic

Marco Alifano a, b, *, Pietro Alifano c, Patricia Forgez d, Antonio Iannelli e, f

a Thoracic Surgery Department, Cochin Hospital, APHP Centre, University of Paris, France
b INSERM U1138 Team «Cancer, Immune Control, and Escape», Cordeliers Research Center, University of Paris, France
Chair of Microbiology, Department of Biological and Environmental Sciences and Technologies, Salento University, Lecce, Italy
INSERM UMR-S 1124 T3E, Equipe 5 CELLULAR HOMEOSTASIS, CANCER and THERAPY, University of Paris, Campus Saint Germain, Paris, France
Digestive Disease Department, Archet 2 Hospital, Nice University Hospital, University of Nice Côte d’Azur, Nice, France
Inserm, U1063, Team 8 "Hepatic Complications of Obesity", University Nice Côte d’Azur, France

A R T I C L E   I N F O

Article history:
Received 2 April 2020
Received in revised form 10 April 2020
Accepted 12 April 2020
Available online 16 April 2020

Keywords:
COVID-19
ACE2
Mechanisms

A B S T R A C T

Significant aspects of COVID-19 pandemic remain obscure. Angiotensin converting enzyme 2 (ACE2), a component of the renin-angiotensin system, whose expression dominates on lung alveolar epithelial cells, is the human cell receptor of SARS-CoV-2, the causative agent of COVID-19. We strongly encourage the concept that thorough considerations of receptor-ligand interactions should be kept at the heart of scientific debate on infection. In this idea, the whole renin-angiotensin system has to be evaluated. We hypothesize that factors related to ethnicity, environment, behaviors, associated illness, and medications involving this complex system are probably responsible for situations regarded as anomalous from both an epidemiological and a clinical point of view, but, taken together, such factors may explain most of the aspects of current outbreak. We decided to use the analogy of a play and speculate about the possible impact in this tragedy of 1) air pollution via the interference of nitrogen dioxide on ACE2 expression; 2) the dual role of nicotine; 3) the hypothetical involvement of ACE2 polymorphisms, the relationships of which with ethnic factors and susceptibility to cardiovascular disease seems intriguing; 4) the impact on the severity of infection of hypertension and related medications acting on the renin/angiotensin system, and, finally, 5) the possible helpful role of chloroquine, thanks to its capacity of modifying ACE2 affinity to the viral spike protein by altering glycosylation. This hypothesis paper is an urgent call for the development of research programs that aim at questioning whether the putative protagonists of this tragedy are real-life actors in COVID-19.

© 2020 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

1. The play

Significant aspects of COVID-19 pandemic progression remain obscure. After its initial spread in China, the pandemic is now progressing at an accelerating rate in western Europe and the United States of America. Yet, in the other regions of the world, the kinetics of diffusion and mortality seem less impressive, and this in spite of globalization of exchanges and travels. With respect to mortality, some comorbidities, namely diabetes and hypertension, usually having a modest impact on the course of severe diseases, seems to play a major role in the course of Severe Acute Respiratory Syndrome (SARS) COVID-19 [1].

* Corresponding author. Thoracic Surgery Department, Cochin Hospital, APHP Centre, University of Paris, 27 rue du Faubourg Saint Jacques, 75014, Paris, France.
E-mail address: marco.alifano@aphp.fr (M. Alifano).

2. The cast

The severe acute respiratory syndrome corona virus –2 (SARS-CoV-2), the causative agent of COVID-19, is a RNA virus with an envelope constituted by spike projections used as a key to enter the cell. SARS-CoV-2 and SARS-CoV (responsible for the 2003 global outbreak) share very high phylogenetic similarities, with 99% identity between their spikes [2]. Therefore it is not surprising that both viruses exploit the same human cell receptor namely angiotensin converting enzyme 2 (ACE2), whose expression dominates on lung alveolar epithelial cells [3]. ACE2 is an 805-amino acids captoprilsensitive carboxypeptidase with a 17-amino acids N-terminal signal peptide and a C-terminal membrane anchor [4]. ACE2 catalyzes the cleavage of angiotensin I into angiotensin 1-9, and of angiotensin II into the vasodilator angiotensin 1-7, thus playing a key role in systemic
blood pressure homeostasis, counterbalancing the vasoconstrictive action of angiotensin II, which is generated by cleavage of angiotensin I catalyzed by ACE [5]. Although ACE2 mRNA is present in all organs, its protein expression dominates on lung alveolar epithelial cells, enterocytes, arterial and venous endothelial cells, and arterial smooth muscle cells [6]. Although it seems evident that lung is a primary target of COVID-19, it is not counterintuitive that associated cardiovascular conditions or related management could interact with susceptibility to infection and/or severity of the clinical course.

3. The scenario

The concept of the modulation of the receptor-ligand interaction (ACE2-COVID-19) and the broad consequences on the host should be kept at the heart of debate. As function and regulation of ACE2 are interrelated to ACE inside the renin-angiotensin system, the whole system has to be taken into account because of its possible impact on probability of COVID-19 infection and severity of clinical course. Thus, molecular, ethnical, environmental, behavioral, and pharmacological factors involving this complex system are probably responsible for situations regarded as anomalous from both an epidemiological and a clinical point of view, but can be, at last in part, explained at light of available knowledge.

4. The tragedy

It has been pointed out that in patients with severe form of COVID-19 disease, comorbidities are frequent. In the Report of the WHO-China Joint Mission on COVID-19, severe disease (dyspnea, respiratory frequency > 30/minute, blood oxygen saturation < 93%, PaO2/FiO2 ratio < 300, and/or lung infiltrates > 50% of the lung field within 24–48 h) accounted for 13.8% of cases, and overall mortality rate was 3.8% (4.7% in men vs. 2.8% in women) [7]. Individuals at highest risk for severe disease and death were those aged over 60 years, and with underlying illnesses including hypertension, diabetes, cardiovascular disease, chronic respiratory disease and cancer. Crude fatality rate was 1.4% in the absence of comorbid conditions, but increased to 7.6%, 8.0%, 8.4%, 9.2% and 13.2% in case of cancer, chronic respiratory disease, hypertension, diabetes, and cardiovascular disease, respectively [7]. In the recent study on 1099 infected patients by Guan et al., hypertension, diabetes mellitus, coronary heart and cerebrovascular diseases were found in 23.7%, 16.2%, 5.8%, and 2.3% of 173 patients with severe disease [8]. The 20th March report from Italian Health authorities on deceased patients showed that 74% of them had arterial hypertension, 63% underlying cardiovascular conditions (ischemic heart disease, 30%, atrial fibrillation, 22%, previous stroke, 11.2%), and 34% diabetes [9].

Although concurrent cardiovascular disease might explain increased mortality in a severe infection responsible for respiratory failure and deterioration of cardiac function, the observations on hypertension warrant urgent speculation and rethinking. Thus, the hypothesis that cigarette smoking is either detrimental or provides a counterintuitive protective effect, warrants specific epidemiologic and clinical studies. A preliminary meta-analysis indicates that active smoking is not associated with severity of coronavirus disease [22]. The possible downregulation of ACE2 associated with a possible decrease of the virus-binding sites may counteract the general increased susceptibility to lung diseases usually observed in smokers.

ACE2 expression regulation: we speculate that the binding of SARS-CoV-2 to ACE2 is likely to alter the function of the latter, and massive loss of ACE2 function could participate in the pathophysiology of cardio-respiratory failure. In animal models, the loss of ACE2 resulted in increased production of reactive oxygen species (ROS) via NADPH oxidase 2 activation, and administration of recombinant ACE2 was shown to inhibit the angiotensin II effects on TGF-β1 activation and collagen production [14]. Recombinant ACE2 pulmonary overexpression attenuates whole aspects of pulmonary
artery hypertension pathophysiology [23], suggesting that its loss of function (as could occur in case of massive binding by viral particles, with subsequent endocytosis and activation of proteolytic cleavage [24]) could participate in the severity of respiratory distress. More importantly, loss of function of ACE2 cannot counterbalance the deleterious effects of Angiotensin II in promoting degradation of cardiac and lung structures and function [24]. Thus, angiotensin II receptor blockers could also potentially exert a protective action in the late phases of SARS COVID-19 by counteracting the negative effects of Angiotensin II.

Arterial hypertension medications: The urgent need of reflection should take into account the effect of medications on ACE2 synthesis, expression, and action whose theoretical impact on COVID-19 prevention, infection, severity, and management would be not negligible. Hypertension involves 1.39 billion people worldwide, 349 million in high-income and 1.04 billion in low- and middle-income countries. However, large discrepancies in exposure to antihypertensive drugs worldwide exist: the awareness, treatment, and control concern 67%, 56%, and 28% of patients in high income, and 37%, 29%, and 7.7% of patients in low- and middle-income countries [25]. Most patients with arterial hypertension and/or cardiac failure are treated by ACE1 inhibitors or angiotensin II receptor blockers (sartans). Prescription of sartans increases each year in high-income countries, and are probably the most frequently prescribed drugs in diabetic patients with hypertension. These medications increase gene expression of ACE2 in rats [26]. Although there are no indications to date that the same situations occurs in humans, this could result in increased binding site for COVID-19 in non-infected cases and in the diffusion phases of viral infection, but, as stated above, could represent part of a therapeutic armamentarium in severely ill patients with compromised cardiorespiratory function. This therapeutic opportunity has been suggested by the march 19, 2020 joint statement of HFSA/ACC/AHA [27]. In this statement, discontinuation of ACE inhibitors or sartans was discouraged for those patients currently prescribed, but the idea of updating these recommendations in the case of evolution in further research and developments was set. A warning signal on the possible impact of these drugs has been published in an authoritative journal [1].

6. Act V (conclusion)

The fact that the renin/angiotensin system ACE and ACE2 is at the center of the discussion is probably due to its potential dual effect in different phases of COVID-19 (Fig. 1). It should be emphasized that chloroquine has been advocated as a potentially effective drug to be administered in CIVID-19 associated pneumonia [28]. In vitro models showed that inhibitory effects are observed either before or after exposure to the SARS-CoV, suggesting both prophylactic and therapeutic advantages [29]. Chloroquine acts by elevating the endosomal pH, and interferes with terminal glycosylation of ACE2, thus negatively influencing the SARS virus-receptor binding as indicated in 2005 by in vitro studies [29]. In the early phase of infection with SARS-Cov-2, chloroquine could reduce the binding of the virus to ACE2 on alveolar lung cells membrane and possibly without interfering with ACE2 function. This would result in a reduction of direct viral cytotoxicity without unbalancing the complex equilibrium of the ACE system especially in the setting of ACE2 overexpression. Ongoing randomized trials will answer the question of usefulness of this medication.

7. The epilogue: from fiction to reality of science

Further data should be urgently gathered to clarify the

---

![Fig. 1. The stage. Scene 1: In the renin angiotensin system, angiotensin-converting enzyme (ACE) cleaves angiotensin I (Ang I) to produce angiotensin II (Ang II). Ang II action is mediated by the angiotensin II receptor type 1 (AT1R). ACE, Ang II, and AT1R appears to promote lung injury. Angiotensin converting enzyme 2 (ACE2) removes a single residue from Ang II to generate the vasodilator Ang-(1–7), counterbalancing the effects of Ang II. The main actions described for Ang-(1–7) are associated with Mas receptor activation. The ACE2/Ang-(1–7)/Mas arm high activation is effective in reducing lung inflammation, fibrosis, and pulmonary artery hypertension. Scene 2: SARS-CoV-2 uses ACE2 as a receptor for entry into the cell, once the S protein has been primed by a serine protease. Scene 3: The expression of ACE2 and the balance of Ang II/Ang 1–7 influence the course of the disease. Accordingly, ACE 2 may be upregulated due to the individual polymorphism, NO2 associated with air pollution, and ACE inhibitors/Sartans. ACE2 affinity for spike protein may be lowered by hydroxy-chloroquine. Sartans may inhibit the deleterious effects of Ang II during the late phase of the infection.

Footnote: Nicotine may have dual action by enhancing ACE and down-regulating ACE2.](image-url)
mechanisms underlying pathophysiology of COVID-19 infection, although available data on viral receptor strongly support the concept that some obscure aspects could have a theoretical explanation; these conjectures need to be proven by specifically designed studies.

Authors contribution

Marco Alifano: Conception, designing and writing.
Pietro Alifano: Conception, designing and writing.
Patricia Forgez: Conception, designing and writing.
Antonio Iannelli: Conception, designing and writing.
The authors have no conflict of interest; IRB approval: N/A.

Funding

The work has been supported by INSERM institutional grants.

Declaration of competing interest

The authors have no conflict of interest.

References

[1] L. Fang, G. Karakulakis, M. Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Published March 11, Lancet Respir Med (2020), https://doi.org/10.1016/S2213-2600(20)30116-8.
[2] J.F.W. Chau, K.H. Kok, Z. Zhu, et al., Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan, Emerg. Microb. Infect. 9 (2020) 221–236.
[3] M. Hoffmann, H. Kleine-Weber, S. Schroeder, et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell (2020 Mar 5), https://doi.org/10.1016/j.cell.2020.02.052 [e-pub].
[4] S.K. Tpinis, N.M. Hooper, R. Hyde, et al., A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captorinsensitive carboxypeptidase, J. Biol. Chem. 275 (43) (2000) 33238–33243.
[5] Y. Zheng, Y. Ma, J. Zhang, et al., COVID-19 and the cardiovascular system, Nat. Rev. Cardiol. (2020), https://doi.org/10.1038/s41569-020-0386-9.
[6] I. Hamming, W. Timens, M.L. Bulthuis, et al., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol. 203 (2) (2004) 631–637, https://doi.org/10.1002/path.1570.
[7] https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. (Accessed 31 March 2020).
[8] Guan WJ, Ni ZY, Hu Y, et al. N Engl J Med February 28, 2020, DOI: 10.1056/NEJMoa200232.
[9] https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo.pdf. (Accessed 31 March 2020).
[10] Q. Zhang, M. Cong, N. Wang, et al., Association of Angiotensin-Converting Enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: a case-control study, Medicine (Baltim.) 97 (42) (2018), e12917.
[11] N. Lu, Y. Yang, Y. Wang, et al., ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects, Mol. Biol. Rep. 39 (6) (2012) 6581–6589, https://doi.org/10.1007/s11033-012-1487-1.
[12] D.S. Pinheiro, R.S. Santos, P.C.B.V. Jardim, et al., The combination of ACE I/D and ACE 8790A polymorphisms reveals susceptibility to hypertension: a genetic association study in Brazilian patients, PloS One 14 (8) (2019), e0221248, https://doi.org/10.1371/journal.pone.0221248.
[13] J. Huang, S. Chen, X. Lu, et al., Polymorphisms of ACE2 are associated with blood pressure response to cold pressor test: the GenSalt study, Am. J. Hypertens. 25 (8) (2012) 937–942, https://doi.org/10.1093/ajh/hpj212.61.
[14] V.B. Patel, J.C. Zhong, M.B. Grant, et al., Role of the ACE2/angiotensin 1-7 Axis of the renin-angiotensin system in heart failure, Circ. Res. 118 (11) (2016) 1313–1326.
[15] J. Meulenbelt, L. van Bree, J.A. Dormans, et al., Biochemical and histological alterations in rats after acute nitrogen dioxide intoxication, Hum. Exp. Toxicol. 11 (3) (1992) 189–200.
[16] J.M. Patel, K.M. Sekharam, E.R. Block, Oxidant injury increases cell surface receptor binding of angiotensin II to pulmonary artery endothelial cells, J. Biochem. Toxicol. 5 (4) (1990) 253–258.
[17] T.C. Kuan, T.H. Yang, C.H. Wen, et al., Identifying the regulatory element for human angiotensin-converting enzyme 2 (ACE2) expression in human cardio-fibroblasts, Peptides 32 (9) (2011) 1832–1839.
[18] B.Y. Yang, Y. Guo, I. Markeyev, et al., Association of long-term exposure to ambient air pollutants with risk factors for cardiovascular disease in China, JAMA Netw Open 2 (3) (2019), e190318.
[19] Y. Cui, Z.F. Zhang, J. Froines, et al., Air pollution and case fatality of SARS in the People's Republic of China: an ecologic study, Environ. Health 2 (1) (2003) 15.
[20] European Space Agency, Le confinement lié au coronavirus entraîne une chute de la pollution à travers l'Europe. http://www.esa.int/Space_in_Member_States/Fl/ce/le_confinement_lie_au_coronavirus_entraine_une_chute_de_la_pollution_a_travers_l_Europe. (Accessed 30 March 2020).
[21] J.M. Oakes, R.M. Fuchs, J.D. Gardner, et al., Nicotine and the renin-angiotensin system, Am. J. Physiol. Regul. Integr. Comp. Physiol. 315 (5) (2018 Nov 1) R895–R906, https://doi.org/10.1152/ajpregu.00099.2018.
[22] G Lippon, BM. Henry, Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19), Eur J Intern Med (2020 Mar 16), https://doi.org/10.1016/j.ejim.2020.03.011 pii: S0953-6205(20)30110-2.
[23] C.T. Cole-Jeffrey, M. Liu, M.J. Katochiv, et al., ACE2 and microbiota: emerging targets for cardiopulmonary disease therapy, J. Cardiovasc. Pharmacol. 66 (6) (2015) 540–550, https://doi.org/10.1097/JCP.0000000000003037.
[24] M. Ghelawie, K. Wang, A. Vivesos, et al., Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system, Circ. Res. (2020), https://doi.org/10.1161/CIRCRESAHA.120.317015. Apr 2020.
[25] K.T. Mills, J.D. Bundy, T.N. Kelly, et al., Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries, Circulation 134 (6) (2016) 441–450.
[26] C.M. Ferrario, J. Jessup, M.C. Chappell, et al., Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation 111 (20) (2005) 2605–2610.
[27] https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. (Accessed 31 March 2020).
[28] G. Garabatos, J. Toghiani, A. Chevalier, et al., Captopril reduces the renin-angiotensin system, Am. J. Physiol. Regul. Integr. Comp. Physiol. 315 (5) (2018 Nov 1) R895–R906, https://doi.org/10.1152/ajpregu.00099.2018.
[29] M.J. Vincent, E. Bergeron, S. Benjannet, et al., Chloroquine is a potent inhibitor of the renin-angiotensin system in heart failure, Circ. Res. 118 (8) (2016) 1313–1326.
[30] J. Cau, J. Cau, F. Cau, et al., Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Published March 11, Lancet Respir Med (2020), https://doi.org/10.1016/S2213-2600(20)30116-8.
[31] J. Oakes, R.M. Fuchs, J.D. Gardner, et al., Nicotine and the renin-angiotensin system, Am. J. Physiol. Regul. Integr. Comp. Physiol. 315 (5) (2018 Nov 1) R895–R906, https://doi.org/10.1152/ajpregu.00099.2018.
[32] G Lippon, BM. Henry, Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19), Eur J Intern Med (2020 Mar 16), https://doi.org/10.1016/j.ejim.2020.03.011 pii: S0953-6205(20)30110-2.
[33] C.T. Cole-Jeffrey, M. Liu, M.J. Katochiv, et al., ACE2 and microbiota: emerging targets for cardiopulmonary disease therapy, J. Cardiovasc. Pharmacol. 66 (6) (2015) 540–550, https://doi.org/10.1097/JCP.0000000000003037.